MarginsXMarginsX
Home › Markets › Health Care › CSBR

Champions Oncology Inc. (CSBR)

CSBR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.68
-0.53% on the day
Market cap
$65.1M
Micro cap
Revenue · 2026
$59.4M
+4.4% on 2025
Net income · 2026
-$1.2M
-2.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-04-30, https://www.sec.gov/Archives/edgar/data/771856/000162828026049834/0001628280-26-049834-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-04-30.

Profile

FieldValue
TickerCSBR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000771856
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2026

LineValue
Revenue$59.4M
Net income-$1.2M
Operating income-$1.1M
Net margin-2.0%
Operating margin-1.9%
Revenue growth+4.4%
Cash$4.9M
Total assets$27.0M
P/E (computed)Net income was not positive
P/S (computed)1.1×

Warning signs

Cash runway
9.4 months
$4.4M cash at July 31, 2026
Share count, 1 year
+0.9%
2025-09-12 to 2026-09-09 · +3.3% over 3 years
Going-concern doubt
No
10-Q filed September 11, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-09-11
Cash and burn$4.4M cash; operating cash flow -$1.4M a quarter.Report 2026-07-31
Shares outstanding13,918,569 (2026-09-09); 13,788,421 a year earlier; 13,479,215 three years earlier.Cover page 2026-09-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-07-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-07-31
$15.2M-$426K-$492K$4.4MNo debt tags$60.7M10-Q 2026-09-11
Q4 2026
2026-04-30
$13.8M-$667K-$2.0M$4.9MNo debt tags$59.4M10-K 2026-07-27
Q3 2026
2026-01-31
$16.6M-$279K-$1.3M$7.1MNo debt tags$57.9M10-Q 2026-03-12
Q2 2026
2025-10-31
$15.0M$268K-$1.7M$8.5MNo debt tags$58.4M10-Q 2025-12-15
Q1 2026
2025-07-31
$14.0M-$466K$600K$10.3MNo debt tags$56.9M10-Q 2026-09-11
Q4 2025
2025-04-30
$12.4M-$1.8M$6.9M$9.8MNo debt tags$56.9M10-K 2026-07-27
Q3 2025
2025-01-31
$17.0M$4.5M$490K$3.2MNo debt tags$58.6M10-Q 2026-03-12
Q2 2025
2024-10-31
$13.5M$728K-$283K$2.8MNo debt tags$53.6M10-Q 2025-12-15

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42016-06-10
Latest annual report10-K2026-07-27
Latest quarterly / interim10-Q2026-09-11
Latest current report8-K2026-10-16
Latest proxyDEFA14A2026-08-28

Source: SEC EDGAR submissions feed, 659 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.7%
1 month-3.9%
3 months-7.3%
Year to date-31.8%
1 year-31.7%
From 52-week high-39.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M
NMRANeumora Therapeutics Inc.$0.3695-13.85%$69.4M
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
PMCBPharmaCyte Biotech Inc.$5.57-16.62%$59.8M
AVXLAnavex Life Sciences Corp.$0.8176-12.42%$75.8M
TNYATenaya Therapeutics Inc.$0.3336-4.47%$76.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier